Octreotide | CAS#83150-76-9 | Somatostatin octapeptide analog

MedKoo Cat#: 596972 | Name: Octreotide

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Octreotide is a potent, long-acting synthetic somatostatin octapeptide analog that inhibits secretion of growth hormone and is used to treat hormone-secreting tumors; diabetes mellitus; hypotension, orthostatic; hyperinsulinism; hypergastrinemia; and small bowel fistula.

Chemical Structure

Octreotide

CAS#83150-76-9 (free base)

Theoretical Analysis

MedKoo Cat#: 596972

Name: Octreotide

CAS#: 83150-76-9 (free base)

Chemical Formula: C49H66N10O10S2

Exact Mass: 1018.4405

Molecular Weight: 1019.25

Elemental Analysis: C, 57.74; H, 6.53; N, 13.74; O, 15.70; S, 6.29

Price and Availability

Size	Price	Availability
1mg	USD 250.00	2 Weeks
5mg	USD 650.00	2 Weeks
10mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

79517-01-4 (acetate) 83150-76-9 (free base) 1607842-55-6 (HCl) 135467-16-2 (pamoate)

Synonym

Octreotide; Longastatin; SMS-201-995; Octreotide-LAR;

IUPAC/Chemical Name

(4R,7S,10S,13S,16S,19R)-13-((1H-indol-3-yl)methyl)-19-((S)-2-amino-3-phenylpropanamido)-10-(4-aminobutyl)-16-benzyl-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide

InChi Key

DEQANNDTNATYII-XOEBDJBESA-N

InChi Code

InChI=1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29-,34+,36+,37+,38+,39-,40+,41+,42+/m1/s1

SMILES Code

[H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC1=O)[C@@H](C)O)C(=O)N[C@H](CO)[C@@H](C)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue.

In vitro activity:

Results revealed that Octreotide notably enhanced cell viability and reduced LDH activity. The levels of inflammatory factors were significantly decreased following Octreotide treatment. Additionally, Octreotide attenuated the apoptotic capacity of LPS-induced BEAS-2B cells, led to the up-regulation of Bcl-2 protein level while cut down the protein levels of Bax and cleaved caspase3. Remarkably, the expression of autophagy-related protein LC3II/I and Beclin1 was elevated after Octreotide administration. Reference: Bioengineered. 2022 Jan;13(1):217-226. https://pubmed.ncbi.nlm.nih.gov/34898367/

In vivo activity:

The aim of the present study was to verify the effects of octreotide on hepatic glycogenesis in rats with HFD‑induced obesity. The body weight, levels of FPG and FINS, and the HOMA index were significantly reduced following octreotide treatment, whereas the decrease in Lee's index, the blood levels of ALT, AST, TC, TG and FFA, and the AUC did not reach statistical significance. Hepatic TG and FFA levels were significantly increased and hepatic glycogen content was significantly decreased in rats with HFD‑induced obesity when compared with those in the control group. Octreotide intervention restored these alterations. Reference: Mol Med Rep. 2017 Jul;16(1):109-118. https://pubmed.ncbi.nlm.nih.gov/28534956/

	Solvent	mg/mL	mM
Solubility
	Water	100.0	98.11

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 1,019.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Zhang S, Tang C, Wang X. Octreotide activates autophagy to alleviate lipopolysaccharide-induced human pulmonary epithelial cell injury by inhibiting the protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway. Bioengineered. 2022 Jan;13(1):217-226. doi: 10.1080/21655979.2021.2012908. PMID: 34898367; PMCID: PMC8805934. 2. Kim SE, Kim J, Lee JY, Lee SB, Paik JS, Yang SW. Octreotide inhibits secretion of IGF-1 from orbital fibroblasts in patients with thyroid-associated ophthalmopathy via inhibition of the NF-κB pathway. PLoS One. 2021 Apr 22;16(4):e0249988. doi: 10.1371/journal.pone.0249988. PMID: 33886620; PMCID: PMC8062018. 3. Kugita M, Nishii K, Yamaguchi T, Suzuki A, Yuzawa Y, Horie S, Higashihara E, Nagao S. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease. PLoS One. 2017 May 18;12(5):e0177934. doi: 10.1371/journal.pone.0177934. PMID: 28542433; PMCID: PMC5436842. 4. Wang XX, Ye T, Li M, Li X, Qiang O, Tang CW, Liu R. Effects of octreotide on hepatic glycogenesis in rats with high fat diet‑induced obesity. Mol Med Rep. 2017 Jul;16(1):109-118. doi: 10.3892/mmr.2017.6586. Epub 2017 May 16. PMID: 28534956; PMCID: PMC5482138.

In vitro protocol:

In vivo protocol:

1. Kugita M, Nishii K, Yamaguchi T, Suzuki A, Yuzawa Y, Horie S, Higashihara E, Nagao S. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease. PLoS One. 2017 May 18;12(5):e0177934. doi: 10.1371/journal.pone.0177934. PMID: 28542433; PMCID: PMC5436842. 2. Wang XX, Ye T, Li M, Li X, Qiang O, Tang CW, Liu R. Effects of octreotide on hepatic glycogenesis in rats with high fat diet‑induced obesity. Mol Med Rep. 2017 Jul;16(1):109-118. doi: 10.3892/mmr.2017.6586. Epub 2017 May 16. PMID: 28534956; PMCID: PMC5482138.

1: Ramesh S, Kudachi S, Basu S. PRRT with (177)Lu-DOTATATE in Carcinoid Heart Disease: a contraindication or a promising treatment approach bettering chances for corrective surgery? J Nucl Med Technol. 2018 Jun 8. pii: jnmt.118.210179. doi: 10.2967/jnmt.118.210179. [Epub ahead of print] PubMed PMID: 29884687. 2: Hvas CL, Ott P, Paine P, Lal S, Jørgensen SP, Dahlerup JF. Obeticholic acid for severe bile acid diarrhea with intestinal failure: A case report and review of the literature. World J Gastroenterol. 2018 Jun 7;24(21):2320-2326. doi: 10.3748/wjg.v24.i21.2320. PubMed PMID: 29881241; PubMed Central PMCID: PMC5989246. 3: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E; NETTER-1 Study Group. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With (177)Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol. 2018 Jun 7:JCO2018785865. doi: 10.1200/JCO.2018.78.5865. [Epub ahead of print] PubMed PMID: 29878866. 4: Luo Y, Chen J, Shen B, Wang M, Cai H, Xu L, Chen L, Chen M, Li ZP, Feng ST. CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold? Eur Radiol. 2018 Jun 6. doi: 10.1007/s00330-018-5512-1. [Epub ahead of print] PubMed PMID: 29876704. 5: Campbell R, McCaffrey N, Brown L, Agar MR, Clark K, Currow DC. Clinician-reported changes in octreotide prescribing for malignant bowel obstruction as a result of an adequately powered phase III study: A transnational, online survey. Palliat Med. 2018 Jun 1:269216318778460. doi: 10.1177/0269216318778460. [Epub ahead of print] PubMed PMID: 29856291. 6: Lubner S, Feng Y, Mulcahy M, O'Dwyer P, Giang GY, Louis Hinshaw J, Deming D, Klein L, Teitelbaum U, Payne J, Engstrom P, Stella P, Meropol N, Benson A. E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist. 2018 May 31. pii: theoncologist.2018-0294. doi: 10.1634/theoncologist.2018-0294. [Epub ahead of print] PubMed PMID: 29853660. 7: Sharma S, Singh AD, Sharma SK, Tripathi M, Das CJ, Kumar R. Gallium-68 DOTA-NOC PET/CT as an alternate predictor of disease activity in sarcoidosis. Nucl Med Commun. 2018 May 30. doi: 10.1097/MNM.0000000000000869. [Epub ahead of print] PubMed PMID: 29851772. 8: Detweiler CJ, Mueller SB, Sung AD, Saullo JL, Prasad VK, Cardona DM. Brincidofovir (CMX001) Toxicity Associated With Epithelial Apoptosis and Crypt Drop Out in a Hematopoietic Cell Transplant Patient: Challenges in Distinguishing Drug Toxicity From GVHD. J Pediatr Hematol Oncol. 2018 May 25. doi: 10.1097/MPH.0000000000001227. [Epub ahead of print] PubMed PMID: 29846280. 9: Casnici C, Lattuada D, Crotta K, Truzzi MC, Corradini C, Ingegnoli F, Tonna N, Bianco F, Marelli O. Anti-inflammatory Effect of Somatostatin Analogue Octreotide on Rheumatoid Arthritis Synoviocytes. Inflammation. 2018 May 26. doi: 10.1007/s10753-018-0808-5. [Epub ahead of print] PubMed PMID: 29804189. 10: Bai J, Liu X, Le Goff L, Gargala G, François A, Ballet JJ, Ducrotte P, Favennec L, Towledahong L. Correction: Octreotide modulates the expression of somatostatin receptor subtypes in inflamed rat jejunum induced by Cryptosporidium parvum. PLoS One. 2018 May 24;13(5):e0198377. doi: 10.1371/journal.pone.0198377. eCollection 2018. PubMed PMID: 29795701; PubMed Central PMCID: PMC5967823. 11: Capdevila J, Teulé A, Barriuso J, Castellano D, Lopez C, Manzano JL, Alonso V, García-Carbonero R, Dotor E, Matos I, Custodio A, Casanovas O, Salazar R; EVERLAR study investigators. Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR study. Oncologist. 2018 May 23. pii: theoncologist.2017-0622. doi: 10.1634/theoncologist.2017-0622. [Epub ahead of print] PubMed PMID: 29794066. 12: Gunaratne K, Austin E, Wu PE. Unintentional sulfonylurea toxicity due to a drug-drug interaction: a case report. BMC Res Notes. 2018 May 21;11(1):331. doi: 10.1186/s13104-018-3404-8. PubMed PMID: 29784014. 13: Kumar R, Gautam M, Prasoon P, Gupta S, Ray SB. Comparison of the peripheral antinociceptive effect of somatostatin with bupivacaine and morphine in the rodent postoperative pain model. Eur J Anaesthesiol. 2018 May 18. doi: 10.1097/EJA.0000000000000825. [Epub ahead of print] PubMed PMID: 29762151. 14: Vuddanda V, Jazayeri MA, Turagam MK, Lavu M, Parikh V, Atkins D, Bommana S, Yeruva MR, Di Biase L, Cheng J, Swarup V, Gopinathannair R, Olyaee M, Ivaturi V, Natale A, Lakkireddy D. Systemic Octreotide Therapy in Prevention of Gastrointestinal Bleeds Related to Arteriovenous Malformations and Obscure Etiology in Atrial Fibrillation. JACC Clin Electrophysiol. 2017 Dec 11;3(12):1390-1399. doi: 10.1016/j.jacep.2017.04.022. Epub 2017 Sep 13. PubMed PMID: 29759670. 15: Lambert GA, Zagami AS. Does somatostatin have a role to play in migraine headache? Neuropeptides. 2018 Jun;69:1-8. doi: 10.1016/j.npep.2018.04.006. Epub 2018 Apr 17. Review. PubMed PMID: 29751998. 16: Vajravelu ME, De León DD. Genetic characteristics of patients with congenital hyperinsulinism. Curr Opin Pediatr. 2018 May 9. doi: 10.1097/MOP.0000000000000645. [Epub ahead of print] PubMed PMID: 29750770. 17: Anaclet C, De Luca R, Venner A, Malyshevskaya O, Lazarus M, Arrigoni E, Fuller PM. Genetic Activation, Inactivation, and Deletion Reveal a Limited And Nuanced Role for Somatostatin-Containing Basal Forebrain Neurons in Behavioral State Control. J Neurosci. 2018 May 30;38(22):5168-5181. doi: 10.1523/JNEUROSCI.2955-17.2018. Epub 2018 May 7. PubMed PMID: 29735555. 18: Pusceddu S, Prinzi N, Raimondi A, Corti F, Buzzoni R, Di Bartolomeo M, Seregni E, Maccauro M, Coppa J, Milione M, Mazzaferro V, de Braud F. Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge. Tumori. 2018 Apr 1:300891618765362. doi: 10.1177/0300891618765362. [Epub ahead of print] PubMed PMID: 29714658. 19: Faron-Górecka A, Kuśmider M, Solich J, Kolasa M, Pabian P, Gruca P, Romańska I, Żurawek D, Szlachta M, Papp M, Antkiewicz-Michaluk L, Dziedzicka-Wasylewska M. Regulation of somatostatin receptor 2 in the context of antidepressant treatment response in chronic mild stress in rat. Psychopharmacology (Berl). 2018 Apr 30. doi: 10.1007/s00213-018-4912-x. [Epub ahead of print] PubMed PMID: 29713785. 20: Chassang L, Langlois I, Loos P, Freire M, O'Toole E. Chylous ascites associated with abdominal trauma and intestinal resection-anastomosis in a pet ferret (Mustela putorius furo). J Am Vet Med Assoc. 2018 May 15;252(10):1272-1278. doi: 10.2460/javma.252.10.1272. PubMed PMID: 29701519.